Charles River Laboratories International, Inc. (NYSE:CRL) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Charles River Laboratories International, Inc. (NYSE:CRL) has received a consensus recommendation of “Moderate Buy” from the fifteen research firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have issued a buy rating on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $259.4375.

CRL has been the subject of a number of analyst reports. Mizuho set a $264.00 price target on Charles River Laboratories International in a research report on Monday, August 10th. Evercore reissued an “outperform” rating on shares of Charles River Laboratories International in a research note on Wednesday, August 5th. Robert W. Baird set a $291.00 target price on shares of Charles River Laboratories International in a report on Thursday, August 6th. CLSA cut shares of Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price target for the company. in a research note on Monday, July 20th. Finally, Sanford C. Bernstein set a $250.00 price target on shares of Charles River Laboratories International in a report on Wednesday, July 1st.

Insider Activity

In related news, CEO Birgit Girshick sold 6,500 shares of the business’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $279.90, for a total transaction of $1,819,350.00. Following the completion of the transaction, the chief executive officer owned 36,013 shares in the company, valued at $10,080,038.70. The trade was a 15.29% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Shannon M. Parisotto sold 5,046 shares of the company’s stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $263.00, for a total value of $1,327,098.00. Following the completion of the transaction, the executive vice president directly owned 4,807 shares in the company, valued at $1,264,241. This trade represents a 51.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 165,990 shares of company stock valued at $42,606,388. 1.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Charles River Laboratories International

Several institutional investors and hedge funds have recently made changes to their positions in the business. California State Teachers Retirement System increased its stake in Charles River Laboratories International by 22,535.2% in the 2nd quarter. California State Teachers Retirement System now owns 12,895,733 shares of the medical research company’s stock worth $2,924,623,000 after buying an additional 12,838,761 shares during the period. Invesco Ltd. boosted its position in Charles River Laboratories International by 115.8% in the 4th quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company’s stock valued at $537,828,000 after buying an additional 1,446,972 shares during the period. Victory Capital Management Inc. grew its stake in Charles River Laboratories International by 9,938.8% in the 4th quarter. Victory Capital Management Inc. now owns 691,474 shares of the medical research company’s stock worth $137,935,000 after acquiring an additional 684,586 shares in the last quarter. Ameriprise Financial Inc. grew its stake in Charles River Laboratories International by 1,491.1% in the 3rd quarter. Ameriprise Financial Inc. now owns 613,604 shares of the medical research company’s stock worth $96,005,000 after acquiring an additional 575,039 shares in the last quarter. Finally, Amundi increased its position in shares of Charles River Laboratories International by 175.2% during the first quarter. Amundi now owns 773,315 shares of the medical research company’s stock worth $133,397,000 after acquiring an additional 492,301 shares during the period. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Trading Down 0.9%

Shares of CRL stock opened at $278.36 on Friday. The company has a market cap of $13.29 billion, a PE ratio of -57.39, a price-to-earnings-growth ratio of 2.75 and a beta of 1.40. Charles River Laboratories International has a 1 year low of $144.26 and a 1 year high of $303.30. The stock’s 50 day simple moving average is $258.38 and its two-hundred day simple moving average is $204.34. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.04.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.25. The firm had revenue of $1 billion during the quarter, compared to analysts’ expectations of $980.53 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The company’s quarterly revenue was down 2.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.12 EPS. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Research analysts predict that Charles River Laboratories International will post 11.33 earnings per share for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.